Helius Medical Technologies Files 8-K on Director Changes and Compensation
Ticker: HSDT · Form: 8-K · Filed: Sep 25, 2025 · CIK: 1610853
| Field | Detail |
|---|---|
| Company | Helius Medical Technologies, Inc. (HSDT) |
| Form Type | 8-K |
| Filed Date | Sep 25, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $890,000, $610,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-change, officer-compensation, filing
TL;DR
Helius Medical Technologies filed an 8-K today covering director changes and executive comp. Keep an eye on leadership moves.
AI Summary
On September 24, 2025, HELIUS MEDICAL TECHNOLOGIES, INC. filed an 8-K report detailing changes in its board of directors and officer compensation arrangements. The filing also includes information on financial statements and exhibits, as well as a Regulation FD disclosure.
Why It Matters
This filing signals potential shifts in the company's leadership and executive pay structure, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: medium — Changes in directors and officer compensation can indicate internal shifts that may affect company strategy and performance.
Key Players & Entities
- HELIUS MEDICAL TECHNOLOGIES, INC. (company) — Registrant
- September 24, 2025 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors'.
What is the nature of the compensatory arrangements discussed?
The filing covers 'Compensatory Arrangements of Certain Officers'.
What is the company's state of incorporation?
HELIUS MEDICAL TECHNOLOGIES, INC. is incorporated in Delaware.
What is the company's IRS Employer Identification Number?
The IRS Employer Identification Number for HELIUS MEDICAL TECHNOLOGIES, INC. is 36-4787690.
What other items are included in this 8-K filing?
This filing also includes 'Regulation FD Disclosure' and 'Financial Statements and Exhibits'.
Filing Stats: 1,063 words · 4 min read · ~4 pages · Grade level 11.1 · Accepted 2025-09-25 09:00:18
Key Financial Figures
- $0.001 — hich registered Class A Common Stock, $0.001 par value HSDT The Nasdaq Stock Mar
- $890,000 — f and Mr. Mathiesen in amounts equal to $890,000 and $610,000, respectively (together, t
- $610,000 — hiesen in amounts equal to $890,000 and $610,000, respectively (together, the "Cash Bonu
Filing Documents
- hsdt-20250924x8k.htm (8-K) — 49KB
- hsdt-20250924xex10d1.htm (EX-10.1) — 25KB
- hsdt-20250924xex10d2.htm (EX-10.2) — 25KB
- hsdt-20250924xex99d1.htm (EX-99.1) — 17KB
- hsdt-20250924x8k001.jpg (GRAPHIC) — 7KB
- hsdt-20250924xex10d1001.jpg (GRAPHIC) — 3KB
- hsdt-20250924xex10d1002.jpg (GRAPHIC) — 6KB
- hsdt-20250924xex10d2001.jpg (GRAPHIC) — 3KB
- hsdt-20250924xex10d2002.jpg (GRAPHIC) — 6KB
- 0001104659-25-093161.txt ( ) — 293KB
- hsdt-20250924.xsd (EX-101.SCH) — 3KB
- hsdt-20250924_lab.xml (EX-101.LAB) — 16KB
- hsdt-20250924_pre.xml (EX-101.PRE) — 10KB
- hsdt-20250924x8k_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 25, 2025, the Company issued a press release announced the filing of its U.S. Food and Drug Administration ("FDA") 510(k) submission for the Portable Neuromodulation Stimulator device label expansion seeking an indication for gait and balance deficit in patients with chronic stroke symptoms. The submission was made with data generated in the Company's Stroke Registrational Program and was filed under its current FDA Breakthrough Device Designation. A copy of the press release is furnished as Exhibit 99.1 to this Report and incorporated herein by reference. Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Report, and the inclusion of such website addresses in this Report by incorporation by reference of the press release is as inactive textual references only. Exhibit 99.1 hereto contains forward-looking statements within the meaning of the federal securities laws. These forward-looking statements are based on current expectations and are not guarantees of future performance. Further, the forward-looking statements are subject to the limitations listed in Exhibit 99.1 and in the other reports of the Company filed with the Securities and Exchange Commission, including that actual events or results may differ materially from those in the forward-looking statements. The information in this Report, including Exhibit 99.1 hereto, is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such 2 filing. The Company's submission of this Report shall not be deemed an admission as t
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Side Letter, dated as of September 24,2025, between the Company and Dane C. Andreeff . 10.2 Side Letter, dated as of September 24,2025, between the Company and Jeffrey S. Mathiesen . 99.1 Press Release, dated September 25, 2025 . 104 Cover Page Interactive Data File (embedded within Inline XBRL document). 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HELIUS MEDICAL TECHNOLOGIES, INC. Dated: September 25, 2025 By: /s/ Jeffrey S. Mathiesen Jeffrey S. Mathiesen Chief Financial Officer, Treasurer and Secretary 4